NANO | Jotup

Nanox Announces Collaboration with AhealthZ and SCL Science to Enter South Korean Market

Retrieved on:

Tuesday, April 9, 2024

Diagnosis, X-ray, LTD, Cardiology, Patient, Science, Radiology, SCL, Department of Tourism (Philippines), NANO, Teleradiology, ARC, Marketing, Medical device

PETAH TIKVA, Israel, April 09, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced a new collaboration to advance the Nanox.ARC 3D imaging system and Nanox artificial intelligence (AI) solutions in Korea with AhealthZ – a distributor of healthcare services and devices – and SCL Science, AhealthZ’s affiliated company and subsidiary of global healthcare group SCL (Seoul Clinical Laboratories).

Key Points:

Under the collaboration, AhealthZ plans to assist Nanox in efforts to secure local authorizations and licenses to enable the importation, marketing and sales of the Nanox.ARC in South Korea.
The Nanox.ARC is a digital tomosynthesis system that uses multiple sources of X-rays to produce a three-dimensional, tomographic images.
The collaboration will also include SCL Science integrating Nanox’s AI solutions in remote image analysis and other operations.
“We are excited to work with AhealthZ and SCL Science to bring our comprehensive medical imaging solutions to South Korea, a country of over 51 million people and one of the world’s most advanced technological markets,” said Erez Meltzer, Nanox Chief Executive Officer.

Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation

Retrieved on:

Tuesday, April 2, 2024

NBTXR3, Lung cancer, NSCLC, Patient, Observation, Cancer, Nanobiotix, NANO, Radiation, MD, University, MD Anderson Cancer Center, Safety, Pharmaceutical industry

The Phase 1 study (“Study 2020-0123”) is being conducted by The University of Texas MD Anderson Cancer Center (“MD Anderson”) as part of an ongoing strategic collaboration with Nanobiotix.

Key Points:

The Phase 1 study (“Study 2020-0123”) is being conducted by The University of Texas MD Anderson Cancer Center (“MD Anderson”) as part of an ongoing strategic collaboration with Nanobiotix.
“NBTXR3 is designed as a product candidate with the potential to improve treatment outcomes for patients with cancer in any setting where radiotherapy is a part of the treatment regimen.
“We believe the injection feasibility and favorable safety profile we have observed from the completed dose escalation part of this Phase 1 lung cancer study could pave the way for additional clinical development of NBTXR3 for patients with inoperable, recurrent lung cancer and patients amenable to re-irradiation.”
The completed dose escalation part of Study 2020-0123 established the recommended Phase 2 dose after determination of injection feasibility and observation of a favorable safety profile.
The expansion part of the study, further evaluating safety and early signals of efficacy, is ongoing.

Nanox Announces Fourth Quarter of 2023 Financial Results and Provides Business Update

Retrieved on:

Monday, April 1, 2024

PETAH TIKVA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced results for the fourth quarter ended December 31, 2023 and provided a business update.

Key Points:

Fourth Quarter 2023 Highlights and Recent Developments:
Generated $2.4 million in revenue in the fourth quarter of 2023, compared to $2.1 million in the fourth quarter of 2022.
“I am incredibly proud to announce another strong quarter and year for Nanox,” said Erez Meltzer, Nanox Chief Executive Officer.
“First and foremost, we achieved a pivotal milestone in fiscal year 2023, getting FDA clearance for the Nanox ARC systems and deploying them in the key US market.
During the fourth quarter of 2023, Nanox AI continued to complete pilot programs with marketplaces, marketplace costumers and health organizations in anticipation of full deployment of its products.

Supermicro Expands Edge Compute Portfolio to Accelerate IoT and Edge AI Workloads with New Generation of Embedded Solutions

Retrieved on:

Tuesday, April 9, 2024

Cloud, HDMI, Temperature, Intel, GPU, Intel Core, Network, Memory, Environment, Internet of things, PCI Express, AI, NANO, DIN, RAM, Intel Atom, Dust, Robotics, Housing, Gigabit Ethernet, Ecosystem, TB, Atom, Total, Video game

SAN JOSE, Calif. and NUREMBERG, Germany, April 8, 2024 /PRNewswire/ -- Supermicro, Inc. (NASDAQ: SMCI), a Total IT Solution Provider for AI, Cloud, Storage, and 5G/Edge, announces a new generation of IoT and embedded systems designed to enhance performance and increase power-efficiency for intelligent applications at the remote edge. With the addition of these new models, including support for the new Intel® Atom® x7000RE processor, Supermicro further enhances its diverse infrastructure solutions to deliver computing and AI performance to the intelligent edge.

Key Points:

With the addition of these new models, including support for the new Intel® Atom® x7000RE processor, Supermicro further enhances its diverse infrastructure solutions to deliver computing and AI performance to the intelligent edge.
"Our building block architecture allows us to design and deliver a wide range of AI servers that give enterprises the solutions they need, from the edge to the cloud.
"They are depending on our ecosystem to deliver solutions for low-power, price-sensitive, and space-constrained environments that can address the wide variety of workloads across the edge."
Addressing the need for an economical solution to run AI inferencing workloads at the edge, Supermicro also introduces the 1U SYS-111AD-WRN2.

Supermicro Expands Edge Compute Portfolio to Accelerate IoT and Edge AI Workloads with New Generation of Embedded Solutions

Retrieved on:

Tuesday, April 9, 2024

SAN JOSE, Calif. and NUREMBERG, Germany, April 9, 2024 /PRNewswire/ -- Supermicro, Inc. (NASDAQ: SMCI), a Total IT Solution Provider for AI, Cloud, Storage, and 5G/Edge, announces a new generation of IoT and embedded systems designed to enhance performance and increase power-efficiency for intelligent applications at the remote edge. With the addition of these new models, including support for the new Intel® Atom® x7000RE processor, Supermicro further enhances its diverse infrastructure solutions to deliver computing and AI performance to the intelligent edge.

Key Points:

With the addition of these new models, including support for the new Intel® Atom® x7000RE processor, Supermicro further enhances its diverse infrastructure solutions to deliver computing and AI performance to the intelligent edge.
"Our building block architecture allows us to design and deliver a wide range of AI servers that give enterprises the solutions they need, from the edge to the cloud.
"They are depending on our ecosystem to deliver solutions for low-power, price-sensitive, and space-constrained environments that can address the wide variety of workloads across the edge."
Addressing the need for an economical solution to run AI inferencing workloads at the edge, Supermicro also introduces the 1U SYS-111AD-WRN2.

Nanox to Report Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024

Retrieved on:

Monday, March 18, 2024

Event, Interest, LTD, NANO

PETAH TIKVA, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter and fiscal year ended December 31, 2023, before market open on Monday, April 1, 2024.

Key Points:

PETAH TIKVA, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter and fiscal year ended December 31, 2023, before market open on Monday, April 1, 2024.
Erez Meltzer, Chief Executive Officer, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m.
Interested parties may register for the conference call using the following link: Nanox Q4 Earnings Call Registration .
You may access the live webcast of the conference call by using the following link: Nanox Q4 Earnings Call Webcast .

Nanobiotix to Present at Upcoming Investor Conferences in March

Retrieved on:

Wednesday, March 6, 2024

NANO, Conference, Patient, Cancer

PARIS and CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate in fireside chats at the upcoming Guggenheim Healthy Altitudes Summit and the Leerink Partners Global Biopharma Conference.

Key Points:

PARIS and CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate in fireside chats at the upcoming Guggenheim Healthy Altitudes Summit and the Leerink Partners Global Biopharma Conference.
Please see below for details on each event.
The fireside chats will be webcast live from the events page of the Investors section of the Company’s website.
Replays of the webcasts will be available following the events.

Sunderstorm Introduces the Next Generation of Functional Gummies, KANHA FX, Formulated by Doctors for Targeted Effects

Retrieved on:

Thursday, February 15, 2024

LOS ANGELES, Feb. 15, 2024 /PRNewswire/ -- Sunderstorm's award-winning edibles brand is proud to welcome KANHA FX, a new line of functional gummies that heralds groundbreaking advancements in precision, innovation and targeted effects. Formulated by doctors to help set your mood, KANHA FX launches with three fast-acting gummies: ENERGY, SLEEP and LOVE.

Key Points:

LOS ANGELES, Feb. 15, 2024 /PRNewswire/ -- Sunderstorm's award-winning edibles brand is proud to welcome KANHA FX, a new line of functional gummies that heralds groundbreaking advancements in precision, innovation and targeted effects.
Formulated by doctors to help set your mood, KANHA FX launches with three fast-acting gummies: ENERGY, SLEEP and LOVE.
"The scientific community knows more about cannabinoids, terpenes and entourage effects today than it has at any time in history," explains Cameron Clarke, CEO and Co-Founder of Sunderstorm.
"As the science advances, our products will follow suit, and that commitment helps make KANHA FX the driving force behind the next generation of functional gummies.

NANO Nuclear Energy to Present and Exhibit at Innovation Zero 2024, the UK’s Largest Net Zero Conference

Retrieved on:

Wednesday, February 14, 2024

Innovation, Material, RT, University of Cambridge, SMR, Public opinion, Government, Entrepreneurship, Carbon, Radiation, Lead, History, Nuclear energy, Congress, NANO, Renewable energy

New York, N.Y., Feb. 14, 2024 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. ("NANO Nuclear"), an emerging microreactor and advanced nuclear technology company led by a world-class nuclear engineering team developing proprietary, portable, and clean energy solutions, is pleased to announce that it is sponsoring the upcoming Innovation Zero 2024 conference in London on April 30 and May 1, 2024.

Key Points:

“We are immensely pleased to sponsor and participate in this exciting event.”
“Our sponsorship of the upcoming Innovation Zero 2024 conference marks a significant milestone for NANO Nuclear,” said James Walker, Chief Executive Officer of NANO Nuclear Energy.
“Innovation Zero is about scaling innovation to drive the low carbon transformation,” Paul Dunne, CEO and Co-Founder of Innovation Zero, commented.
Our participation in Innovation Zero will provide even greater momentum to this inspirational national project.”
Figure 3 – Prof. Ian Farnan, Lead of Nuclear Fuel Cycle, Radiation and Materials of NANO Nuclear Energy to Attend Innovation Zero 2024.
The UK has long been a hub of innovation, particularly in the nuclear sector and it's a great honor to represent NANO Nuclear at a globally recognized event such as this.”
Figure 5 – Prof. Eugene Shwageraus, Lead of Nuclear Reactor Engineering of NANO Nuclear Energy to Attend Innovation Zero 2024.

Idaho National Laboratory Completes Pre-Conceptual Review of NANO Nuclear Energy’s Proprietary Low-Pressure Coolant Microreactor “ODIN”

Retrieved on:

Monday, February 5, 2024

NANO, United States national laboratories, Void coefficient, INL, Idaho National Laboratory, United, Lead, Skylon (spacecraft), Uranium mining

NEW YORK, NY, Feb. 05, 2024 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. ("NANO Nuclear"), an emerging microreactor and advanced nuclear technology company, led by a world-class nuclear engineering team developing proprietary, portable, and clean energy solutions, announced that Idaho National Laboratory (INL) has completed a pre-conceptual design review of NANO Nuclear’s “ODIN” low-pressure coolant microreactor design.

Key Points:

NEW YORK, NY, Feb. 05, 2024 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. ("NANO Nuclear"), an emerging microreactor and advanced nuclear technology company, led by a world-class nuclear engineering team developing proprietary, portable, and clean energy solutions, announced that Idaho National Laboratory (INL) has completed a pre-conceptual design review of NANO Nuclear’s “ODIN” low-pressure coolant microreactor design.
The review was requested by NANO Nuclear to provide an external audit of the technical work completed to date on the “ODIN” microreactor.
NANO Nuclear expects that INL will perform a similar review of its proprietary “ZEUS” microreactor in February 2024.
“Working alongside Idaho National Laboratory and their team of esteemed professionals has been immensely beneficial to NANO Nuclear,” said James Walker, NANO Nuclear Energy’s CEO and Head of Nuclear Reactor Development.